Ipamorelin vs CJC-1295
Two of the most-studied growth-hormone-releasing research peptides, compared.
Ipamorelin and CJC-1295 are frequently studied together and often compared. Both target growth-hormone pathways in preclinical models, but through different receptors.
Side-by-side
| Attribute | Ipamorelin | CJC-1295 |
|---|---|---|
| Peptide class | Pentapeptide ghrelin-mimetic | GHRH analog |
| Studied mechanism | GH release via the ghrelin / GHS receptor | GH release via the GHRH receptor |
| Selectivity note | Noted for minimal cortisol / prolactin effect in research | DAC version is longer-acting |
| Common research context | GH-pulse and body-composition models | GH-axis and metabolic models |
| Often studied together | Yes — a classic research pairing | Yes — a classic research pairing |
Which does the research favor?
They are complementary rather than competing — the literature frequently pairs a GHRH analog (CJC-1295) with a ghrelin-mimetic (Ipamorelin) to study synergistic GH release.
Explore both compounds
Each ships with its Certificate of Analysis. Compare, then choose the compound that fits your research question.
For research use only. These products are intended solely for in-vitro laboratory research and are not for human or veterinary use. Nothing here is medical advice or a therapeutic claim.